09:45 AM EST - Eupraxia Pharmaceuticals Inc. : Today announced 36-week tissue health and symptom data from patients in the highest dose cohort from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis. Eupraxia Pharmaceuticals Inc.
shares T.EPRX are trading unchanged at $9.90.
